17 results match your criteria crs + hipec group

  • Page 1 of 1

Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience.

J Gastrointest Cancer 2019 Dec;50(4):709-715

Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA.

Purpose: Adenocarcinoma ex-goblet cell carcinoids (AGCCs) are rare appendiceal tumors with mixed neuroendocrine and glandular features. They tend to behave more aggressively than typical carcinoid tumors, affect younger patients, and have a greater predilection for spreading to the peritoneum. Outcomes of AGCC patients treated with chemotherapy, extrapolated from colon cancer regimens, in the adjuvant or metastatic setting have not been explicitly reported. Read More

View Article and Full-Text PDF
December 2019

The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133+ CXCR4.

Pancreatology 2016 Jul-Aug;16(4):632-9. Epub 2016 May 12.

Servicio de Cirugía General y de Aparato Digestivo, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.

Objective: The origin of pancreatic cancer has been identified as a population of malignant pancreatic stem cells CD133+ CXCR4+ immunophenotype. These cells have high capacity for early locoregional invasion, being responsible for early recurrence and high mortality rates of pancreatic cancer. We propose a study for decreasing tumor progression of pancreatic cancer by reducing the volume and neoplastic subpopulation of pancreatic cancer stem cells CD133+ CXCR4+. Read More

View Article and Full-Text PDF

Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).

Eur J Surg Oncol 2015 May 17;41(5):707-12. Epub 2015 Jan 17.

Department of Surgical Oncology, Mercy Medical Center, 227 St Paul Place, Baltimore, MD 21202-2001, USA. Electronic address:

Background: The role of SC before CRS/HIPEC for patients with PMCA is unclear. This study explores the effect of SC prior to CRS/HIPEC on overall survival (OS) in patients with PMCA.

Methods: 72 patients with recently diagnosed PMCA who underwent CRS/HIPEC were identified from a prospective database. Read More

View Article and Full-Text PDF

Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.

BMC Cancer 2014 Nov 4;14:807. Epub 2014 Nov 4.

Department of Surgery, University Hospital Regensburg, 93042 Regensburg, Germany.

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide an effective treatment option for selected patients with colorectal peritoneal metastasis with encouraging survival results. Many different drug combinations and HIPEC regimens including bidirectional, i.e. Read More

View Article and Full-Text PDF
November 2014

Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.

Minerva Chir 2014 Feb;69(1):17-26

Istituto di Clinica Chirurgica Centro di Riferimento Regionale Neoplasie Peritoneali Università di Chieti, Chieti, Italy -

Aim: The present study reports our experience concerning with the advanced cancer treatment (cytoreductive surgery and hyperthermic intraperitoneal chemotherapy) in patients with advanced ovarian cancer ephitelial (AEOS) or recurrent ovarian cancer ephitelial (REOC).

Methods: In a period from October 2006 to December 2009, we observed 25 patients affected by advanced ephitelial ovarian cancer or recurrent ephitelial ovarian cancer. All patients underwent CRS + HIPEC procedures. Read More

View Article and Full-Text PDF
February 2014

Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.

Ann Surg Oncol 2014 Jun 15;21(6):1792-800. Epub 2013 Dec 15.

Department of Digestive Disease, Hôpital Lariboisière-AP-HP & Université Diderot-Paris 7, Paris, France,

Background: Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy. The aim of this study was to analyze the potential impact of bevacizumab on early morbidity after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis of colorectal origin.

Methods: From 2004 to 2010, in three referral centers, 182 patients with colorectal carcinomatosis were treated with complete cytoreduction followed by HIPEC after either preoperative systemic chemotherapy alone or in combination with bevacizumab. Read More

View Article and Full-Text PDF

Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer.

Int J Hyperthermia 2012 1;28(8):735-41. Epub 2012 Nov 1.

Department of Traditional Chinese Medicine, School of Medicine, Jinan University, Huangpu Road West 601, Guangzhou, P.R. China.

Background: Currently known as a metastatic disease, stage IV gastric cancer cannot be cured by surgery, but treatments are recommended to relieve symptoms such as pain and to prolong survival.

Methods: With better access to metastases and certain large or inoperable tumours, we applied two treatment sessions of combined therapy of whole-body hyperthermia and hyperthermic intraperitoneal chemo-perfusion in the treatment group, while patients in the control group were treated with oxaliplatin combined with 5-fluorouracil chemotherapy or Xeloda. We used the RECIST criteria for outcome evaluation. Read More

View Article and Full-Text PDF

Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.

J Surg Oncol 2013 Mar 18;107(4):307-11. Epub 2012 Jul 18.

Department of Surgery, Duke University, Durham, NC 27710, USA.

Background: The treatment of metastatic colorectal cancer (CRC) has evolved rapidly over the last decade, with combination chemotherapy and targeted biologic agents leading to significant improvements in survival. Despite these advances, little is known about their effectiveness in CRC-associated peritoneal carcinomatosis. The purpose of this study was to evaluate outcomes in patients with CRC-associated PC treated in the era of modern chemotherapy. Read More

View Article and Full-Text PDF

Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model.

Int J Colorectal Dis 2010 Feb 10;25(2):245-50. Epub 2009 Nov 10.

Department of General, Visceral, Vascular and Thoracic Surgery, University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.

Purpose: Surgical cytoreduction of peritoneal surface malignancy of colorectal origin in combination with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) has become an established treatment approach. Only a few of animal models for scientific research on various therapeutic strategies have been described yet. The feasibility of an established rat model with a peritoneal surface malignancy from colorectal origin for treatment investigation should be examined in this study. Read More

View Article and Full-Text PDF
February 2010

Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.

Ann Surg Oncol 2010 Jan 26;17(1):296-303. Epub 2009 Aug 26.

Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA.

Background: Hyperthermic intraperitoneal (IP) chemotherapy after cytoreduction improves survival in patients with colorectal carcinomatosis of the peritoneal surface. Most protocols use single agents (mitomycin C or oxaliplatin) provided IP. The purpose of this study was to determine whether combination IP chemotherapy is superior to single-agent therapy in a mouse model. Read More

View Article and Full-Text PDF
January 2010

Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

J Clin Oncol 2009 Feb 22;27(5):681-5. Epub 2008 Dec 22.

Département de Chirurgie Carcinologique, Institut Gustave Roussy, Villejuif, France.

Purpose: To compare the long-term survival of patients with isolated and resectable peritoneal carcinomatosis (PC) in comparable groups of patients treated with systemic chemotherapy containing oxaliplatin or irinotecan or by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).

Patients And Methods: All patients with gross PC from colorectal adenocarcinoma who had undergone cytoreductive surgery plus HIPEC from 1998 to 2003 were evaluated. The standard group was constituted by selecting patients with colorectal PC treated with palliative chemotherapy during the same period, but who had not benefited from HIPEC because the technique was unavailable in the center at that time. Read More

View Article and Full-Text PDF
February 2009

"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Eur J Surg Oncol 2009 Apr 28;35(4):434-8. Epub 2008 Mar 28.

Department of Surgical Oncology, Institut Gustave Roussy, Cancer Centre, Villejuif Cédex, France.

Background: Combining complete cytoreductive surgery (CCRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a new approach allowing curatively intended treatment of multiple malignant peritoneal tumour seedings. This aggressive treatment is frequently followed by a complicated or an unusual postoperative course, that has yet to be described.

Aim: To describe the clinical and biological post-therapeutic course of patients treated with CCRS plus HIPEC, who were considered uncomplicated cases, and were discharged from hospital before the 15th postoperative day. Read More

View Article and Full-Text PDF

Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.

Ann Surg Oncol 2008 May 22;15(5):1407-13. Epub 2007 Dec 22.

Division of Surgical Oncology, UMDNJ-New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, USA.

Background: Cytoreduction coupled with hyperthermic intraperitoneal chemotherapy (HIPEC) is an attractive treatment option for a select group of patients with abdominal-only malignancy. The present phase I study examined the safety and pharmacokinetics of intraperitoneal pegylated liposomal doxorubicin (PLD) used in the context of HIPEC in patients with advanced abdominal-only malignancies.

Methods: Patients with advanced abdominal malignancies underwent maximal cytoreduction and HIPEC with escalating doses of PLD (15-100 mg/m(2)). Read More

View Article and Full-Text PDF

[Effects of hyperthermic chemotherapy on gastrointestinal cancer cells in vitro].

Ai Zheng 2006 Aug;25(8):974-8

Department of Abdominal Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.

Background & Objective: Little evidence is known from experimental research for intraoperative hyperthermic intraperitoneal chemotherapy. This study was to investigate the effect of hyperthermic chemotherapy on gastrointestinal cancer cells in vitro and explore the possible factors which may affect this method.

Methods: Gastric cancer cell line MGC-803 and intestinal cancer cell line HCT-116 were chosen. Read More

View Article and Full-Text PDF

Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies.

World J Gastroenterol 2005 Jul;11(28):4300-4

Department of Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.

Aim: To compare the effect, adverse events, cost-effectiveness and dose intensity (DI) of oral Xeloda vs calcium folinate (CF)/5-FU combination chemotherapy in patients with advanced gastrointestinal malignancies, both combined with bi-platinu two-way chemotherapy.

Methods: A total of 131 patients were enrolled and randomly selected to receive either oral Xeloda (X group) or CF/5-FU (control group). Oral Xeloda 1,000 mg/m2 was administered twice daily from d 1 to 14 in X group, while CF 200 mg/m2 was taken as a 2-h intravenous infusion followed by 5-FU 600 mg/m2 intravenously for 4-6 h on d 1-5 in control group. Read More

View Article and Full-Text PDF

Pharmacokinetics of intraperitoneal gemcitabine in a rat model.

Tumori 1998 Nov-Dec;84(6):706-11

The Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.

Background: Gemcitabine (2'-2' difluorodeoxycytidine) has been shown to possess a broad spectrum of antitumor activity against various malignancies, particularly pancreatic carcinoma. For cancers occurring within the abdominal cavity, the advantage of intraperitoneal (i.p. Read More

View Article and Full-Text PDF

[Studies on hyperthermia by the use of a thermosensitizing drug].

Gan To Kagaku Ryoho 1986 Jan;13(1):60-4

Hyperthermic treatment using ACNU combined with a thermosensitizing drug, methylglyoxal-bis-guanylhydrazone (MGBG), was studied in human gastric cancer xenotransplanted into nude mice. In order to increase the intra-cellular MGBG content, intraperitoneal injection of alpha-difluoromethylornithine(DFMO) 1000 mg/kg was performed twice with an interval of 6 hours and 50 mg/kg of MGBG was given at the time of the second administration of DFMO. After 6 hours of MGBG administration, ACNU 20 mg/kg was given intraperitoneally and, subsequently a 23-minute hyperthermia was carried out in a water bath at 43. Read More

View Article and Full-Text PDF
January 1986
  • Page 1 of 1